| Charles Romberger, MD | |
|
555 N Duke St, Lancaster, PA 17602-2250 | |
| (717) 544-5511 | |
| Not Available |
| Full Name | Charles Romberger |
|---|---|
| Gender | Male |
| Speciality | Pathology |
| Experience | 38 Years |
| Location | 555 N Duke St, Lancaster, Pennsylvania |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1760422752 | NPI | - | NPPES |
| 6900500 | Medicaid | NJ | |
| 0551432000 | Other | AMERIHEALTH | |
| 1076004 | Other | MHP |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207ZP0102X | Pathology - Anatomic Pathology & Clinical Pathology | MD432856 (New Jersey) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Lancaster General Hospital | Lancaster, PA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Lancaster General Hospital | 1254240039 | 408 |
News Archive
Human cells are able to secrete a cancer-killing protein, scientists at the University of Kentucky's Markey Cancer Center have found.
UCLA scientists have for the first time identified a new sodium-dependent mechanism to deliver glucose—the body's main fuel that drives tumor growth—to pancreatic and prostate cancer cells, offering new hope in the fight against two of the deadliest forms of the disease.
In conjunction with the Charing Cross International Symposium (CX34), which concludes today in London, Minneapolis-based Medtronic, Inc. announced its plans for the imminent start of the IN.PACT Global SFA clinical study, an international research program to evaluate the treatment of peripheral artery disease using the company's IN.PACT Admiral drug-eluting balloon.
In the lead up to its first pledging conference on June 13, the GAVI Alliance announced today it has achieved commitments from two emerging market vaccine manufacturers to lower prices for the life-saving pentavalent vaccine, which protects against five deadly diseases. Developed country manufacturers have also offered price reductions on rotavirus and human papillomavirus, or HPV, vaccines.
Custom-tailored antibodies are regarded as promising weapons against a multitude of serious illnesses. Since they can accurately recognize specific structures on the surface of viruses, bacteria or cancer cells, they are already being deployed successfully in cancer diagnostics and therapy, as well as against numerous other diseases. The stability of the sensitive antibodies is a decisive factor in every step, from production and storage to therapeutic application.
› Verified 6 days ago
| Entity Name | Lancaster General Hospital |
|---|---|
| Entity Type | Part B Supplier - Hospital Department(s) |
| Entity Identifiers | NPI Number: 1265535645 PECOS PAC ID: 1254240039 Enrollment ID: O20040413001177 |
News Archive
Human cells are able to secrete a cancer-killing protein, scientists at the University of Kentucky's Markey Cancer Center have found.
UCLA scientists have for the first time identified a new sodium-dependent mechanism to deliver glucose—the body's main fuel that drives tumor growth—to pancreatic and prostate cancer cells, offering new hope in the fight against two of the deadliest forms of the disease.
In conjunction with the Charing Cross International Symposium (CX34), which concludes today in London, Minneapolis-based Medtronic, Inc. announced its plans for the imminent start of the IN.PACT Global SFA clinical study, an international research program to evaluate the treatment of peripheral artery disease using the company's IN.PACT Admiral drug-eluting balloon.
In the lead up to its first pledging conference on June 13, the GAVI Alliance announced today it has achieved commitments from two emerging market vaccine manufacturers to lower prices for the life-saving pentavalent vaccine, which protects against five deadly diseases. Developed country manufacturers have also offered price reductions on rotavirus and human papillomavirus, or HPV, vaccines.
Custom-tailored antibodies are regarded as promising weapons against a multitude of serious illnesses. Since they can accurately recognize specific structures on the surface of viruses, bacteria or cancer cells, they are already being deployed successfully in cancer diagnostics and therapy, as well as against numerous other diseases. The stability of the sensitive antibodies is a decisive factor in every step, from production and storage to therapeutic application.
› Verified 6 days ago
| Entity Name | University Of Penn - Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1235527342 PECOS PAC ID: 6204730955 Enrollment ID: O20141111000091 |
News Archive
Human cells are able to secrete a cancer-killing protein, scientists at the University of Kentucky's Markey Cancer Center have found.
UCLA scientists have for the first time identified a new sodium-dependent mechanism to deliver glucose—the body's main fuel that drives tumor growth—to pancreatic and prostate cancer cells, offering new hope in the fight against two of the deadliest forms of the disease.
In conjunction with the Charing Cross International Symposium (CX34), which concludes today in London, Minneapolis-based Medtronic, Inc. announced its plans for the imminent start of the IN.PACT Global SFA clinical study, an international research program to evaluate the treatment of peripheral artery disease using the company's IN.PACT Admiral drug-eluting balloon.
In the lead up to its first pledging conference on June 13, the GAVI Alliance announced today it has achieved commitments from two emerging market vaccine manufacturers to lower prices for the life-saving pentavalent vaccine, which protects against five deadly diseases. Developed country manufacturers have also offered price reductions on rotavirus and human papillomavirus, or HPV, vaccines.
Custom-tailored antibodies are regarded as promising weapons against a multitude of serious illnesses. Since they can accurately recognize specific structures on the surface of viruses, bacteria or cancer cells, they are already being deployed successfully in cancer diagnostics and therapy, as well as against numerous other diseases. The stability of the sensitive antibodies is a decisive factor in every step, from production and storage to therapeutic application.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Charles Romberger, MD Po Box 3555, Lancaster, PA 17604-3555 Ph: (717) 544-5511 | Charles Romberger, MD 555 N Duke St, Lancaster, PA 17602-2250 Ph: (717) 544-5511 |
News Archive
Human cells are able to secrete a cancer-killing protein, scientists at the University of Kentucky's Markey Cancer Center have found.
UCLA scientists have for the first time identified a new sodium-dependent mechanism to deliver glucose—the body's main fuel that drives tumor growth—to pancreatic and prostate cancer cells, offering new hope in the fight against two of the deadliest forms of the disease.
In conjunction with the Charing Cross International Symposium (CX34), which concludes today in London, Minneapolis-based Medtronic, Inc. announced its plans for the imminent start of the IN.PACT Global SFA clinical study, an international research program to evaluate the treatment of peripheral artery disease using the company's IN.PACT Admiral drug-eluting balloon.
In the lead up to its first pledging conference on June 13, the GAVI Alliance announced today it has achieved commitments from two emerging market vaccine manufacturers to lower prices for the life-saving pentavalent vaccine, which protects against five deadly diseases. Developed country manufacturers have also offered price reductions on rotavirus and human papillomavirus, or HPV, vaccines.
Custom-tailored antibodies are regarded as promising weapons against a multitude of serious illnesses. Since they can accurately recognize specific structures on the surface of viruses, bacteria or cancer cells, they are already being deployed successfully in cancer diagnostics and therapy, as well as against numerous other diseases. The stability of the sensitive antibodies is a decisive factor in every step, from production and storage to therapeutic application.
› Verified 6 days ago
Sarah Reynolds Nassau, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 555 N Duke St, Lancaster, PA 17602 Phone: 717-544-5511 | |
Dr. Wayne Ross, M.D. Pathology Medicare: Not Enrolled in Medicare Practice Location: 1689 Crown Ave, Suite 5, Lancaster, PA 17601 Phone: 717-481-8510 | |
Dr. Mark C Regan, M.D. Pathology Medicare: Accepting Medicare Assignments Practice Location: 1761 Wicklawn Dr, Lancaster, PA 17603 Phone: 717-293-8380 | |
Grace Wheeler Weyant, Pathology Medicare: Accepting Medicare Assignments Practice Location: 555 N Duke St, Lancaster, PA 17602 Phone: 717-544-5511 | |
Dr. Shashi Baksh, M.D. Pathology Medicare: Medicare Enrolled Practice Location: 2301 Harrisburg Pike, Suite 201, Lancaster, PA 17601 Phone: 717-393-7771 Fax: 717-393-7328 | |
Susan Mary Bator, M.D. Pathology Medicare: Accepting Medicare Assignments Practice Location: 555 N Duke St, Lancaster, PA 17602 Phone: 717-544-5511 | |
Xingcao Nie, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 555 North Duke St, Lancaster, PA 17602 Phone: 717-544-5511 Fax: 717-544-5138 |